Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, announced that the California Institute for Regenerative Medicine (C...
As biopharmaceutical innovation continues to evolve, analytical science is playing a more strategic role in accelerating development and supporting regulat...
Non-dilutive funding will support the commercialization, development, and expansion strategy for Sonire's Ultrasound-Guided HIFU Platform Sonire Therape...
Jetstream Venture Fund (Jetstream), an innovative interval fund dedicated to opening access to institutional-grade deal flow for a wider mainstream audienc...
Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing o...
VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), underscored its industry leadership in the dev...
Clinical Trial approval for TCX-001 is another significant development milestone for T-CURX and marks the transition of T-CURX from a pre-clinical to a...
-Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, announced an alliance with bit.bio to create a comp...
G-Link enables targeted in vivo delivery and streamlines ex vivo workflows without lentiviral vector reengineering G-Link supports multiple delivery...
United Immunity, Co., Ltd., a biotechnology company developing its proprietary Myeloid Targeting Platform™ for therapeutic in vivo engineerin...
Endeavor® Live Cell enables rapid kinetic imaging across large scale screening campaigns, generating the cellular data needed to support Lab-in-...
The state-of-the-art facility enhances support for complex modalities across all phases of drug development Key facts Thermo Fisher opens new bioanal...
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positiv...
To address the critical need for accelerated decision-making and de-risked progression from discovery to Chemistry, Manufacturing, and Controls (CMC) in ...
© 2026 Biopharma Boardroom. All Rights Reserved.
